Regeneron Pharmaceuticals Inc (REGN.O): Initial Thoughts on 2Q26 - Broad commercial beat, though Dupixent GTN Aids upside

研报英文原文证据摘录

Regeneron Pharmaceuticals Inc (REGN.O): Initial Thoughts on 2Q26 - Broad commercial beat, though Dupixent GTN Aids upside

the contrary, within EU Member States, the Product is made available by Citigroup Global Markets Europe

AG ("CGME"), which is regulated by the European Central Bank and the German Federal Financial Supervisory Authority

(Bundesanstalt für Finanzdienstleistungsaufsicht-BaFin).

The Product is not to be construed as providing investment services in any jurisdiction where the provision of such services

would not be permitted.

Subject to the nature and contents of the Product, the investments described therein are subject to fluctuations in price

and/or value and investors may get back less than originally invested. Certain high-volatility investments can be subject to

sudden and large falls in value that could equal or exceed the amount invested.The yield and average life of CMOs

(collateralized mortgage obligations) referenced in this Product will fluctuate depending on the actual rate at which mortgage

holders prepay the mortgages underlying the CMO and changes in current interest rates. Any government agency backing of

the CMO applies only to the face value of the CMO and not to any premium paid. Certain investments contained in the Product

may have tax implications for private customers whereby levels and basis of taxation may be subject to change. If in doubt,

investors should seek advice from a tax adviser. The Product does not purport to identify the nature of the specific market or

other risks associated with a particular transaction. Advice in the Product is general and should not be construed as personal

advice given it has been prepared without taking account of the objectives, financial situation or needs of any particular

investor.